NanoViricides (NNVC) 10-Q2010 Q3 Quarterly report

Filed: 20 May 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	8th grade Avg

New words: accrue, af, al, Allergy, Alternatively, amendedby, analyzed, anniversary, arrangement, Article, ASC, automatically, average, award, Barton, biochemistry, building, ca, cap, Capita, cGMP, Chairman, character, Cheryl, classified, col, complement, condition, confidence, connection, consecutive, contingent, corroboration, coverage, criteria, currency, customary, dataset, deliverable, delivery, denominated, detailed, discounted, divided, ealth, element, eligible, employment, enti, entirety, essential, expenditure, explained, feature, ffective, firm, fledged, Floor, fourteenth, Francisco, ginning, gle, Hepat, herpesviral, hold, ial, ideal, immunology, indemnify, industry, infec, insurance, IP, ity, Jayant, Ken, lack, lan, letter, liquidation, lower, LP, mark, met, microbiology, Midtown, multiplied, ndidate, negative, NEOUCOM, NIAID, NIH, Northeastern, Ohio, onset, pa, Package, pany, party, pattern, personnel, Pharmacy, PhD, plural, progression, Purch, Randall, ready, Register, registered, REMOVED, repurposing, resul, retrospective, retrospectively, RNA, Rosenthal, ry, sala, salary, San, screening, se, Seaside, serve, shelf, sin, singular, starter, statistical, Stoddart, subscrip, substantive, suited, Tatake, ted, ter, tient, trademark, tranche, ts, ty, UCSF, underway, uniform, uniformity, vendor, verity, Vice, volume, VWAP, weighted, zosteriform

Removed: Armed, assuming, CRADA, CT, Department, disclosing, doubt, grant, offer, permissive, principle, realization, Reed, revoke, satisfaction, spending, USAFIP, Walter, WRAIR

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NNVC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q (the “Report”) of NanoViricides, Inc. (the “Company”) for the quarter ended March 31, 2010, each of the undersigned Eugene Seymour, the Chief Executive Officer of the Company, and, the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of the undersigned’s knowledge and belief:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 20, 2010	/s/ Eugene Seymour
	Eugene Seymour
	Chief Executive Officer and Interim
	Chief Financial Officer and Director
	(Principal Executive, Accounting and Financial Officer)